Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SH1573 in R/R AML with IDH2 Mutation
NCT04806659Phase 1Unknown
- Sponsor
- Nanjing Sanhome Pharmaceutical Co., Ltd.
- Start
- Aug 2020
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of enflunibu in acute myeloid leukemia (AML), sponsored by Nanjing Sanhome Pharmaceutical Co., Ltd. Primary endpoints: Dose-limiting toxicity up to 28 days, Number of Participants With Adverse Events and 1 more. Status: unknown.
02
Drugs
enflunibu
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04806659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04806659.